{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:16:31Z","timestamp":1782461791266,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1053\/j.seminhematol.2010.02.006","type":"journal-article","created":{"date-parts":[[2010,6,20]],"date-time":"2010-06-20T20:46:42Z","timestamp":1277066802000},"page":"274-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Thrombocytopenia in Patients With Myelodysplastic Syndromes"],"prefix":"10.1053","volume":"47","author":[{"given":"Jeffrey","family":"Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.02.006_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF02994001","article-title":"Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics","volume":"73","author":"Aul","year":"2001","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2002.1.136","article-title":"Myelodysplastic syndromes","author":"Greenberg","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.56.082103.104704","article-title":"Myelodysplastic syndrome","volume":"56","author":"Hofmann","year":"2005","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1634\/theoncologist.2-6-389","article-title":"Understanding the myelodysplastic syndrome","volume":"2","author":"Kouides","year":"1997","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib7","first-page":"161","article-title":"Myelodysplastic syndromes","volume":"151","author":"Doll","year":"1989","journal-title":"West J Med"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib8","first-page":"1286","article-title":"Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes","volume":"87","author":"Alessandrino","year":"2002","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2010.02.006_bib9","first-page":"s24","article-title":"Platelet aggregation and its clinical significance in the myelodysplastic syndromes","volume":"23","author":"Mittelman","year":"1999","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10384-005-0228-6","article-title":"Ocular complications in myelodysplastic syndromes as preleukemic disorders","volume":"49","author":"Kezuka","year":"2005","journal-title":"Jpn J Ophthalmol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.1994.tb04895.x","article-title":"Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases","volume":"87","author":"Wattel","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib12","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib13","first-page":"153","article-title":"Low dose Ara-C for patients with myelodysplastic syndromes","volume":"2","author":"Powell","year":"1988","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00000421-199704000-00018","article-title":"Phase II study of roquinimex in myelodysplastic syndrome","volume":"20","author":"Rosenfeld","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1986.4.4.589","article-title":"13-cis retinoic acid treatment for myelodysplastic syndromes","volume":"4","author":"Picozzi","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib16","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cncr.11810","article-title":"Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses","volume":"98","author":"Wu","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.1188","article-title":"Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome","volume":"68","author":"Lee","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0145-2126(99)00113-7","article-title":"Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications","volume":"23","author":"Gupta","year":"1999","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib19","first-page":"893","article-title":"Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome","volume":"9","author":"Konstantopoulos","year":"1989","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1537-2995.2004.03288.x","article-title":"Blood collection and transfusion in the United States in 1999","volume":"45","author":"Sullivan","year":"2005","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0037-1963(00)90047-7","article-title":"Current issues with platelet transfusion in patients with cancer","volume":"37","author":"McCullough","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib22","author":"Besa"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib23","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/jama.1987.03390130095036","article-title":"Platelet transfusion therapy","volume":"257","year":"1987","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib24","author":"Sepulveda"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1537-2995.1997.37697335157.x","article-title":"Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets","volume":"37","author":"Gelb","year":"1997","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/1096-8652(200008)64:4<251::AID-AJH3>3.0.CO;2-N","article-title":"Platelet transfusions: utilization and associated costs in a tertiary care hospital","volume":"64","author":"Meehan","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1537-2995.2001.41121493.x","article-title":"Transfusion-transmitted bacterial infection in the United States, 1998 through 2000","volume":"41","author":"Kuehnert","year":"2001","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/cryo.2001.2306","article-title":"Human platelets loaded with trehalose survive freeze-drying","volume":"42","author":"Wolkers","year":"2001","journal-title":"Cryobiology"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib29","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib30","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2010.02.006_bib32","first-page":"357","article-title":"Combined immunosuppressive treatment in patients with early myelodysplasia","volume":"90","author":"Cermak","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2004.03.016","article-title":"Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells","volume":"28","author":"Deeg","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdi007","article-title":"Low-dose interleukin-11 in patients with bone marrow failure: update of the M.D","volume":"16","author":"Tsimberidou","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib35","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2001.19.21.4165","article-title":"Pilot study of low-dose interleukin-11 in patients with bone marrow failure","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib36","series-title":"Neumega (oprelvekin) prescribing information","year":"2006"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib37","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V85.11.3066.bloodjournal85113066","article-title":"A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia","volume":"85","author":"Gordon","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib38","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib39","first-page":"112","article-title":"Effects of pegylated recombinant human megakaryocyte growth and developement factor on haematopoiesis in patients with aplastic anemia and myelodysplastic syndrome","volume":"29","author":"Urabe","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib40","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-126-9-199705010-00001","article-title":"Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer","volume":"126","author":"Vadhan-Raj","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"issue":"15S","key":"10.1053\/j.seminhematol.2010.02.006_bib43","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2009.27.15_suppl.7009","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS) [abstract]","volume":"27","author":"Sekeres","year":"2009","journal-title":"J. Clin. Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib45","first-page":"224","article-title":"Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract]","volume":"112","author":"Kantarjian","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib46","first-page":"1769","article-title":"Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract]","volume":"114","author":"Greenberg","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.02.006_bib47","first-page":"1770","article-title":"Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving Lenalidomide [abstract]","volume":"114","author":"Lyons","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18","key":"10.1053\/j.seminhematol.2010.02.006_bib48","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:30Z","timestamp":1758522030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0037196310000314"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.02.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombocytopenia in Patients With Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}